Group One Trading
KLRS

Group One Trading’s Kalaris Therapeutics KLRS Stock Holding History

Group One Trading’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$1.16K – 8436
2023
Q2 		$1.36K Buy
+17
New +$1.62K ﹤0.01% 7194
2022
Q1 		– Sell
-9
Closed -$3K – 8864
2021
Q4 		$3K Buy
+9
New +$4.17K ﹤0.01% 7823

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Group One Trading's KLRS Position: Q3 2023 in Review

Group One Trading sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 17 shares — an estimated $1.16K sold.

Group One Trading first reported a position in KLRS in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Group One Trading reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Group One Trading sold 17 Kalaris Therapeutics shares in Q3 2023, an estimated $1.16K.
  • Group One Trading first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 2 quarters.
  • Group One Trading's Kalaris Therapeutics position peaked at $3K in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.